Want to see ACXP full AI Analyst Report?
ACXP Stock Chart & Stats
$2.78
-$0.07(-8.37%)
At close: 4:00 PM EST
$2.78
-$0.07(-8.37%)
Day’s Range― - ―
52-Week Range$1.33 - $9.98
Previous CloseN/A
Volume243.54K
Average Volume (3M)1.14M
Market Cap
$6.66M
Enterprise Value-$6.81M
Total Cash (Recent Filing)$9.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Aug 14, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.91
Shares Outstanding4,297,738
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.91
Forecast
1Y Price Target
$17.00Price Target Upside511.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy (Phase II)Phase II's high cure rate and zero observed recurrence among cured patients provide durable proof-of-concept that materially lowers clinical and regulatory risk. This strengthens the confirmatory evidence package for a single pivotal trial and supports long-term approval prospects and adoption.
Regulatory TailwindsThe FDA's single‑trial guidance and LPAD pathway structurally reduce the typical evidence burden for CDI approval. Over months this decreases required trial scale and cost, shortening timelines and improving the feasibility of a registrational pathway for an oral CDI therapy.
Balance Sheet Strength — No DebtHaving no debt is a durable financial advantage: it lowers fixed obligations, preserves flexibility in choosing financing or partnerships, and reduces bankruptcy risk. This structural strength improves strategic optionality while the company pursues costly development milestones.
Bears Say
Limited Cash & Cash BurnPersistent negative operating and free cash flow with modest cash on hand creates a structural funding gap for capital‑intensive Phase III work. Over the next several months the company will need significant external capital, increasing dilution risk and uncertainty around program continuity.
Pre-Revenue & Ongoing LossesBeing pre‑revenue with recurring net losses means the business lacks internally generated funding and depends on trial success or external financing. Structurally this raises long-term execution risk, limits reinvestment capacity, and magnifies the impact of any funding delays.
Small Early-Stage RCDI DataA 20‑patient open‑label pilot yields limited statistical power and regulatory credibility. Structurally, reliance on small, nonrandom data means larger controlled trials will likely be required, increasing cost, timeline and outcome uncertainty despite favorable guidance.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $1.32 and its highest was $9.98 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $6.66M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Aug 14, 2026 which is in 26 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.58.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 4,297,738 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went down -5.963%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$17.00
▲(511.51% Upside)
Technical Analysis
Ownership Overview
55.41%
Insiders
1.06% Mutual Funds
0.34% Other Institutional Investors
42.46% Public Companies and
Individual Investors